Skip to main content
Post-surgery melanoma drug Opdivo shows promise in trial

A comparison of drug treatments to prevent a recurrence of melanoma following surgery suggests the newer drug, Opdivo, prevented recurrences to a greater degree than the standard treatment, Yervoy, according to findings presented at the European Society for Medical Oncology annual meeting and published in The New England Journal of Medicine online. About 71% of patients taking Opdivo were recurrence-free after one year, while 61% of those taking Yervoy did not experience a recurrence.

Full Story: